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Control of b-Branching in Kalimantacin Biosynthesis: Application 
of Direct Observe 13C NMR to Polyketide Programming 
 
Paul D Walker[a], Christopher Williams[a], Angus NM Weir[a], Luoyi Wang[a], John Crosby[a], Paul R 
Race[b], Thomas J Simpson[a], Christine L Willis*[a], Matthew P Crump*[a] 
 
Abstract: The presence of b-branches in the structure of polyketides 
that possess potent biological activity underpins their widespread 
importance. Kalimantacin is a polyketide antibiotic with selective 
activity against staphylococci and its biosynthesis involves the 
unprecedented incorporation of three different and sequential b-
branching modifications. Here we use purified single and multi-
domain enzyme components of the kalimantacin biosynthetic 
machinery to address in vitro how the pattern of b-branching in 
kalimantacin is controlled. Robust discrimination of enzyme products 
required the development of a generalisable assay, taking advantage 
of direct observe 13C NMR of a single carbon-13 label incorporated 
into key biosynthetic mimics combined with favourable dynamic 
properties of an acyl carrier protein.  We report a previously 
unassigned modular enoyl-CoA hydratase (mECH) domain and the 
assembly of enzyme constructs and cascades that are able to 
generate each specific b-branch.  
Kalimantacin 1 (Figure 1) is a polyketide antibiotic isolated from 
Alcaligenes sp. YL-02632S and Pseudomonas fluorescens with 
high selectivity for staphylococcal species and no resistant strains 
reported.[1] Its full structure and stereochemistry was determined 
by a combination of degradation and stereoselective synthesis of 
the resulting fragments.[2] This study also confirmed that 
kalimantacin and batumin, isolated from Pseudomonas batumici 
are the same compound.[3] It is produced by a hybrid type I trans-
acyltransferase (AT) polyketide synthase (PKS) non-ribosomal 
peptide synthase (NRPS).[1, 4] In these systems, core assembly of 
a polyketide proceeds with the iterative extension of acyl units via 
a ketosynthase (KS) catalysed decarboxylative condensation of 
typically malonyl units supplied by the trans-acting AT as well as 
incorporation of amino acids. The growing intermediate is 
tethered as a thioester to an acyl carrier protein (ACP). Variable 
in-cis reductive domains combine with modifications from trans-
acting domains and further downstream functionalisations to 
introduce structural diversity into the product. Rational 
manipulation of these pathways to deliver biologically optimised 
products remains an important goal. 
 
b-Branching is a common modification that arises through the 
interaction of a trans-acting 3-hydroxy-3-methylglutaryl CoA-
synthase (HCS) containing cassette with a b-ketothioester bound 
to a modular acceptor ACP (ACPA).[5]  Kalimantacin incorporates 
four b-branches: an a,b unsaturated b-branch (endo-b-methyl) at 
C-3, a b,g unsaturated b-branch (exo-b-methylene) at C-7 and two 
saturated b-methyls at C-5 and C-15. Although all three examples 
have been previously observed (Supplementary Figure 1 and 
references therein), the presence of all three types in a single 
molecule is unique as are the sequential introduction of branches 
at C-3, C-5 and C-7. The mechanisms by which this is controlled 
are not understood.  
   
Figure 1. Incorporation of an endo-b-methyl branch by an HCS cassette. 
Kalimantacin 1 with b-branch points highlighted in green. 
The most common HCS cassette that controls b-branching 
contains a free-standing, donor ACP (termed ACPD, BatA in the 
kalimantacin pathway), a decarboxylating KS (KSQ, BatB) and a 
3-hydroxy-3-methylglutaryl synthase (HMGS, BatC). Previously 
we have shown that structural features of ACPA, including a 
tryptophan ‘flag’ are essential for molecular recognition by HMGS 
and therefore the timing on this b-branch incorporation.[6]  Two 
enoyl CoA hydratase (ECH) domains (BatD and BatE) that belong 
to the crotonase superfamily (CS) of enzymes complete the set of 
five enzymes (Figure 1).[5] The mechanism proceeds KSQ 
catalysed generation of acetyl-ACP (Ac-ACPD) and condensation 
with a b-ketothioester-ACPA and HMGS to give HMG-ACPA. 
Dehydration by ECH1 generates 3-methylglutaconyl (MG)-ACPA 
and decarboxylation by ECH2 furnishes an unsaturated b-
branched polyketide branch following reprotonation by ECH2. 
Figure 1 specifically shows the formation of an endo-b-methyl 
branch, however, additional tailoring domains may also be 
present and influence the nature of the final b-branch introduced 
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Almost all pathways that incorporate alternative single (eg pederin, 
onnamide) or multiple (phormidolide) exo-b-methylene branches 
are commonly associated with modular ECH domains with a KS-
ECH-ECH-ACP(1-3) architecture (Supplementary Figure 1). These 
ECH2 domains act in-cis rather than in-trans and are inserted 
specifically at the point of exo-b-methylene incorporation.[4b] Bat3, 
which incorporates the three sequential b-branches including the 
exo-b-methylene at C7, has been reported to contain four 
elongating modules (9-12) and an off-loading module (13) but no 
modular ECH2-like domain,[1] implying that b-branching is 
controlled by a single trans-acting HCS cassette (BatA-E) and the 
free-standing ER (BatK)[1] (Figure 2A). However, BLAST identified 
a previously unassigned domain in the large inter-domain linker 
region (328 aa) between ACP4 and the downstream KS in module 
11 with 53.9% identity to BatE. This matches the point of exo-b-
methylene incorporation and suggests that this modular ECH2 
may control this step (Figure 2B).[7]  
 
Figure 2. A) Original assigned domain order of ORF Bat3[1] and below the 
upated domain order to include the previously unassigned ECH domain (shown 
in pink). The linker lengths between catalytic domains are shown in blue. B) 
Proposed mechanism for the formation of β-branches in the kalimantacin 
biosynthetic pathway. The exo-β-methylene may be made via one of two routes. 
(i) Decarboxylation and C-2 reprotonation of MG-ACP by mECH. (ii) mECH-
catalysed isomerism of an endo-β-methyl. 
An exo-b-methylene may, however, arise from either (i) the 
modular ECH2 intercepting the dehydrated product via 
decarboxylation and alternative reprotonation at the C-2 position 
before the trans-acting ECH2 can access it or (ii) the modular 
ECH2 catalysed isomerisation of an endo-b-methyl branch or 
(Figure 2B). Only the kalimantacin and phormidolide pathways 
are now known to have two ECH2 domains, and therefore either 
route is feasible. CS family members are notoriously difficult to 
functionally classify based on amino acid sequence or 3D 
architecture[8] and homology modelling did not reveal the 
likelihood of mECH catalysing either of these reactions.  
 
Previous characterisation of b-branching pathways used protein 
MS, in particular the phosphopantetheine (Ppant) ejection assay 
(MS-eject), as the primary method of determining product 
formation.[5, 7] However, MS cannot resolve double bond isomers 
so UV absorption, GC/MS of hydrolysed intermediates and 2H-
labelling have been applied.[9] To allow for a more detailed 
characterisation of b-branching pathways in general, we designed 
an in vitro NMR assay to monitor the chemical shift of an ACP-
bound 13C-label selectively incorporated into a biosynthetic mimic 
that would discriminate either regioisomer and take advantage of 
the favourable transverse relaxation properties of a mobile Ppant 
side-arm.  
 
The HCS cassette (BatA, C-E), modular ACP4-6, modular ECH 
(mECH) and reductase (BatK) were recombinantly over-
expressed in E. coli and purified (Supplementary Figures 2 and 
3). Both BatD and BatE were trimeric by size exclusion 
chromatography (SEC).[8] Pantetheine-bound biosynthetic 
intermediates were prepared from 2: Ac-pantetheine 3, 
acetoacetyl (Acac)-pantetheine 4, HMG-pantetheine 5, 3-
methylbut-2-enoyl-pantetheine 6 and [2-13C]-Ac-pantetheine 8 
(Scheme 1 and Supplementary Material and Methods, 
Supplementary Schemes 1-3) and used ass substrates for 
enzymatic reactions or converted chemoenzymatically to the 
corresponding CoAs for transfer onto apo-ACP.[10]  
Scheme 1. A) Preparation of functionalised-ACP in a one-pot, in situ 
chemoenzymatic pantetheine upgrade and ACP-loading reaction. Biosynthetic 
pathway to derivatised CoA with the new functional groups added to pantetheine 
derivatives by CoaA, CoaD and CoaE shown in green, orange and blue 
respectively. The phosphopantetheine arm (black) is transferred to apo-ACP by 
a PPTase (here MupN) to give functionalised ACP. B) Acyl-pantetheines. * 
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13C-NMR confirmed the 13C-label could be readily observed on 
derivatised ACPs. Apo-BatA was loaded with [13C]-Ac-
pantetheine 8 yielding a single 13C NMR signal at 32.75 ppm 
(Figure 3A). Similarly, a 13C-label could be observed on a modular 
ACP, [13C]-Ac-ACP4. (Supplementary Figure 4).  
 
Figure 3. 13C DEPT spectra and MS-eject assays for ACP4 endo-β-methyl 
branch generation. A) Acetyl 13C-methyl signal of [13C]-Ac-BatA (orange) with 
the observed 13C atom highlighted with a red circle. Inset: MS-eject for [13C]-Ac-
BatA. B) Acac-ACP4 + [13C]-Ac-BatA + BatC showing [13C]-methylene of BatA-
HMG (purple) and 13C-methyl of hydrolysed acetate (green). C) 13C DEPT and 
D) 1H-13C HSQC of Acac-ACP4 + [13C]-Ac-BatA + BatC + BatD + BatE. MS-
eject derived signals endo-b-methyl-ACP4 (344.2 Da) and Acac-ACP4 (345.2 
Da).  
The reaction of Acac-ACP4, [13C]-Ac-BatA and the HMGS BatC 
was assayed (Figure 3B) and the 13C spectrum showed the 
presence of two new signals. The first, at 50.15 ppm, was inverted 
in a DEPT experiment and was consistent with the CH2 of an 
ACP-bound HMG-intermediate. The peak at 26.00 ppm was 
assigned to free [13C]-acetate generated via hydrolysis of [13C]-
Ac-BatC.[11] MS-eject assay validated the formation of the [13C]-
HMG-ACP4 (406.2 Da). 
 
Next BatD and BatE were incubated with [13C]-HMG-ACP4 and 
the reaction cascade monitored by DEPT (Figure 3C). A new 
positive signal at 23.51 ppm emerged and by MS-eject (344.2 Da) 
and 1H-13C HSQC correlations (Figure 3D) confirmed the 
formation of (Z)- [4-13C]- 3-methylbutenoyl-ACP4. Reconstitution 
of the same pathway using ACP5 and assay by NMR/MS 
(Supplementary Figure 5) and ACP6 by MS (data not shown) 
gave identical results. 
 
ECH1 and ECH2 domains are metabolically coupled[12] and 
incubations with BatD alone did not yield [13C]-MG-ACP4. To 
characterise the dehydrated MG intermediate, HMG-
pantetheine 5 was incubated with BatD and BatE and monitored 
by 1H NMR. Although reactions were significantly slower than with 
ACP-bound intermediates, we detected trace quantities of the 
MG-pantetheine 9 and 3-methylbut-2-enoyl-pantetheine 6 
(Supplementary Figure 6). 2D NOESY confirmed the syn-
assignment of the methylene group and alkene proton of 9. 
 
Initially, to determine whether mECH could complement for BatE 
and act as a decarboxylase, HMG-pantetheine 5 was incubated 
with BatD and mECH. The production of the dehydrated 
intermediate 9 or pantetheine 7 was measured by both NMR and 
MS but no unsaturated-b-methyl product was observed. 
Pantetheine 6 was incubated with mECH to monitor for isomerism 
of the a,b-unsaturated bond, but NMR detected no changes. 
Subsequent structural characterisation suggested incorrectly 
folded mECH (Supplementary Figure 7). To overcome this 
challenge, a di-domain of ACP4-mECH (4M) that preserved the 
native linker between the ACP and ECH domain was cloned, 
expressed and purified. The protein was dimeric by SEC (86 kDa) 
and 15N labelling of 4M followed by acquisition of a 1H-15N HSQC 
spectrum showed improved dispersion of resonances 
(Supplementary Figure S7), consistent with the construct being 
folded. To determine whether a 13C signal was still visible, [13C]-
Ac-pantetheine 8 was loaded onto 4M. Despite the high overall 
molecular mass, the 13C label yielded a clear positive CH3 peak 
at 32.75 ppm in the DEPT spectrum (Supplementary Figure 8).  
 
To determine if 4M was functional and able to complement for 
BatE, Acac-4M was first incubated with BatC and [13C]-Ac-BatA 
to give [13C]-HMG-4M, confirming 4M to be a viable substrate for 
the HMGS. Freshly prepared [13C]-HMG-4M was then incubated 
with BatD alone and a new, negatively phased peak at 118.63 
ppm was observed, consistent with an exo-b-methylene chemical 
shift and matched the chemical shifts of an exo-b-methylene 
pantetheine standard 7 (Figure 4). Concurrent MS analysis 
yielded a MS-eject ion at 344.2 Da, consistent with a [13C]-
unsaturated b-branch. No endo-b-methyl peak was observed and 
analogous assays with ACP4 alone gave no MS-eject signal at 
344.2 Da, ruling out spontaneous decarboxylation. A second peak 
at 42.10 ppm may arise from the dehydrated intermediate and 
was consistent with shifts recorded for free diacid equivalents.[13] 
This clearly demonstrated that when partnered with ACP4, mECH 
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Figure 4. 13C NMR (DEPT) and MS-eject of the β-branching pathway for the di-
domain 4M reaction cascade. A) [13C]-Ac-BatA (orange). Inset: MS-eject of Ac-
BatA. B) Acac-4M + [13C]-Ac-BatA + BatC assay. The [13C]-CH2 of BatA-HMG 
is shown in purple and the 13CH3 signal of hydrolysed acetate in green.   C) 
Acac-4M + [13C]-Ac-BatA + BatC + BatD assay. The NMR signal of the 13C exo-
methylene group is shown in pink and the dehydrated MG in yellow. Inset: eject 
assay of decarboxylated product. D) exo-b-methylene pantetheine standard 7.  
 
Finally, [4-13C]-HMG-4M was incubated with both BatD and BatE. 
The reaction contains both possible decarboxylase domains, 
creating the possibility of competition for the formation of either 
an endo-β-methyl or exo-b-methylene. 13C-DEPT spectra yielded 
the expected signal corresponding to the exo-b-methylene but the 
endo-b-methyl product was also observable (Supplementary 
Figure 9). In this case both signals were very weak and the 
presence of [13C]-Ac-BatA and [13C]-HMG-4M, in addition to the 
dehydrated intermediate at 42.10 ppm, suggested that the flux 
through the pathway was inefficient or stalled and it was not 
possible to validate this result by MS due to low yields.  
 
Two saturated b-methyl branches are also formed in kalimantacin 
biosynthesis, firstly, when the biosynthetic intermediate is 
attached to the ACP in module 6 located on Bat2, and secondly, 
when attached to ACP5 on Bat3 (module 12). The saturated b-
methyl is hypothesised to be formed via the reduction of an HCS 
cassette derived endo-b-methyl by a trans-acting ER domain 
(BatK).[1, 14] To elucidate the selectivity of BatK, ACPs derivatised 
with 6 were incubated with BatK and NADH and assayed by MS 
(Figure 5).[15]  
 
The MS-eject assay with ACP5 showed the production of a new 
ion (345 Da) after 1 h and complete consumption of the starting 
material (343 Da) confirming reduction as expected. Enoyl-ACP6 
was not reduced under the same conditions, or after 6 h of 
monitoring, which was consistent with the presence of the 
unsaturated endo-b-methyl group in kalimantacin. Surprisingly 
ACP4 which would not normally bear a substrate for BatK, was 
fully reduced after 1h. No reduction was observed by incubating 
the ACPs with NADH in the absence of BatK. 
 
In this study we have combined carbon-13 isotopic labelling, NMR 
and MS to dissect the mechanism of the different b-branching 
pathways. Importantly this approach takes advantage of the 
fundamental property of an ACP to ‘display’ polar intermediates 
at the end of a dynamic phosphopantetheine arm rather than 
sequester them.[16] Combined with single site 13C enrichment and 
13C-observe cryoprobe technology, we have demonstrated facile 
monitoring of polyketide intermediate processing in an extended 
enzyme cascade. We observe no background 13C signal from 
natural abundance protein signals when attached to either a 
single ACP or the dimeric 4M di-domain (86 kDa) and the 13C 
signal remains sharp. Uniquely this ACP based approach avoids 
the problems associated with fast transverse relaxation rates that 
would normally be associated with studying systems of this size 
and should be a useful tool for studying other related PKS 
systems.  
 
Figure 5. A) BatK catalysed reduction of enoyl-ACP and position of ACP4, 5 
and 6 in the PKS and MS-eject ions are shown. (B-D) MS-eject assay of enoyl-
ACP4, 5 or 6 respectively before (top row) and after (bottom) addition of BatK.  
The presence of a functional modular ECH2 domain at the point 
of exo-methylene b-branching in the kalimantacin brings this 
pathway in line with other PKSs. A comparison with related 
pathways (Supplementary Figure 1) shows that the di-domain 
ACP3-4 followed by the modular ECH2 is reversed compared to 
all other characterised systems and only contains a single 
modular ECH. All other related modules contain two apparent 
sequential modular ECHs although invariably the first of these is 
truncated and most likely non-functional. The modular ECH2 
required the presence of the upstream ACP4 for acitivity and 
unlike other members of this decarboxylase family, it is dimeric 
rather than trimeric.[17] It is therefore likely that the ECH2 folds via 
the ‘self-association’ mechanism whereby the active site is 
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stabilising interactions with either or both the ACP4 and linker 
region.  
 
Formation of the C-7 exo-b-methylene branch at ACP4 therefore 
proceeds via an in-cis mECH mediated decarboxylation and C2 
selective reprotonation. Our in vitro results show, however, that 
BatE - ACP4/4M protein-protein interactions are compatible and 
can yield an endo-b-methyl branch. It is therefore possible for 
BatE (and subsequently BatK) to access ACP4 so this must be 
efficiently suppressed in vivo. Subsequently ACP5 and ACP6 
interact with BatC-E but only ACP5 is recognised by BatK.  
 
b-Branching is therefore partially directed by ACP selectivity but 
must include elements of structural and substrate control. For 
example, increased flux of biosynthetic intermediates channelled 
from ACP4 to the in-cis mECH rather than BatE can ensure exo-
b-methylene branch formation. However, the synthase must first 
permit BatD access to ACP4 and subsequently occlude BatE. 
Conformational dynamics of the PKS and proximity effect may 
ensure the dehydrated product is rapidly channelled to the mECH. 
Conformational rearrangements of a module from the pikromycin 
modular cis-AT PKS have been shown to be important to allow an 
ACP-bound intermediate to interact with different catalytic 
domains and similar mechanisms may operate here.[18] trans-AT 
PKSs may represent an additional level of sophistication however, 
requiring control of the order of both cis and trans functionalities.[6, 
19] The control required for the selective interaction of modular 
ACPs with trans-acting domains is poorly understood and offers 
an exciting area for future research.  
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